GRAIL Inc. (GRAL)
GRAIL Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $108.52, up 0.00% on the session, giving a market capitalisation of $4.66B. On trailing twelve-month figures it carries a trailing P/E of -11.13, a net margin of -236.9%. Its beta of 3.25 implies it has historically moved more than the broad market.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAIL Inc. is most often compared with the following Healthcare names: